OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot...

Area of Science:

• Dermatology and Gerontology
• Molecular Biology and Aging Research

Background:

• The skin, the body's largest organ, is crucial for defense but declines with age, impacting overall health.
• Age-related skin changes compromise barrier integrity and may have systemic consequences.

Purpose of the Study:

• To evaluate the efficacy of a topical senotherapeutic peptide, OS-01, in counteracting age-related skin deterioration.
• To assess the impact of OS-01 on skin parameters, subjective perceptions, and systemic inflammation.

Main Methods:

• A 12-week randomized, double-blind clinical trial with 60 female participants (aged 60-90).
• Comparison of OS-01 topical formulation against a standard moisturizer control.
• Assessment of skin hydration, transepidermal water loss (TEWL), pH, cytokine levels, and biological age (GlycanAge).

Main Results:

• OS-01 significantly improved skin barrier function and hydration compared to the control.
• Participants using OS-01 reported better skin appearance (70% vs. 42%).
• OS-01 reduced pro-inflammatory cytokine IL-8 and suggested a slowing of systemic aging, while the control group showed increased TNF-ɑ and IFN-γ.

Conclusions:

• Topical OS-01 enhances skin barrier function and hydration, potentially mitigating age-related skin decline.
• The formulation may influence systemic inflammation and slow biological aging, highlighting the skin's role in overall health.
• Targeting skin health with senotherapeutics offers a novel approach to promoting longevity and integrated health management.